000258916 001__ 258916
000258916 005__ 20230709000347.0
000258916 0247_ $$2doi$$a10.1101/2023.06.29.547008
000258916 0247_ $$2altmetric$$aaltmetric:150789167
000258916 037__ $$aDZNE-2023-00688
000258916 1001_ $$0P:(DE-2719)9000491$$aBlersch, Josephine$$b0$$eFirst author$$udzne
000258916 245__ $$aAn ex vivo human model for safety assessment of immunotoxicity of engineered nanomaterials
000258916 260__ $$c2023
000258916 3367_ $$0PUB:(DE-HGF)25$$2PUB:(DE-HGF)$$aPreprint$$bpreprint$$mpreprint$$s1688650697_17443
000258916 3367_ $$2ORCID$$aWORKING_PAPER
000258916 3367_ $$028$$2EndNote$$aElectronic Article
000258916 3367_ $$2DRIVER$$apreprint
000258916 3367_ $$2BibTeX$$aARTICLE
000258916 3367_ $$2DataCite$$aOutput Types/Working Paper
000258916 520__ $$aThe unique physicochemical properties of nanomaterials (NM) and engineered nanomaterials (ENM) have pushed their use in many applications ranging from medicine to the food industry, textiles, and many more fields. Thus, human exposure to NM and ENM is growing by the day. However, the current toxicity tests do not reflect the special characteristics of ENM and are not developed for ENM risk assessment. Here we propose a high-throughput cell-based assay using human peripheral blood mononuclear cells (PBMCs) that can monitor the effects of NM and ENM on cytotoxicity and innate immunity. The proposed assay is fully automated and miniaturized, with excellent assay performance parameters (Z-prime-score >0.5), amenable for large screening campaigns in an industrial setting. Immunotoxicity data for ENM safety assessment are collected in dose-response format. At different states, multiparametric readouts for cytotoxicity, and innate immunity are conducted in a combinatorial method, avoiding ENM-induced bias by endotoxin contamination. Integrating this high-dimensional data allows (i) holistic safety assessment of immunotoxicity effects caused by ENM, classifying safe and toxic ENM phenotypes, and (ii) deconvolving mode of action of the ENM effect on the PBMCs. As added value the data obtained can be used to troubleshoot ENM or for a safe-by-design approach in product development.
000258916 536__ $$0G:(DE-HGF)POF4-899$$a899 - ohne Topic (POF4-899)$$cPOF4-899$$fPOF IV$$x0
000258916 588__ $$aDataset connected to CrossRef
000258916 7001_ $$0P:(DE-2719)2810323$$aKurkowsky, Birgit$$b1$$udzne
000258916 7001_ $$0P:(DE-2719)9000668$$aMeyer-Berhorn, Anja$$b2$$udzne
000258916 7001_ $$aGrabowska, Agnieszka Katarzyna$$b3
000258916 7001_ $$aFeidt, Eva$$b4
000258916 7001_ $$aJunglas, Ellen$$b5
000258916 7001_ $$0P:(DE-2719)2810635$$aRoth, Wera$$b6$$udzne
000258916 7001_ $$0P:(DE-2719)2812160$$aStappert, Dominik$$b7$$udzne
000258916 7001_ $$aKuebelbeck, Armin$$b8
000258916 7001_ $$0P:(DE-2719)2810245$$aDenner, Philip$$b9$$udzne
000258916 7001_ $$0P:(DE-2719)2159508$$aFava, Eugenio$$b10$$eLast author$$udzne
000258916 773__ $$a10.1101/2023.06.29.547008
000258916 8564_ $$uhttps://www.biorxiv.org/content/10.1101/2023.06.29.547008v1
000258916 909CO $$ooai:pub.dzne.de:258916$$pVDB
000258916 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)9000491$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b0$$kDZNE
000258916 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)2810323$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b1$$kDZNE
000258916 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)9000668$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b2$$kDZNE
000258916 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)2810635$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b6$$kDZNE
000258916 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)2812160$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b7$$kDZNE
000258916 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)2810245$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b9$$kDZNE
000258916 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)2159508$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b10$$kDZNE
000258916 9131_ $$0G:(DE-HGF)POF4-899$$1G:(DE-HGF)POF4-890$$2G:(DE-HGF)POF4-800$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bProgrammungebundene Forschung$$lohne Programm$$vohne Topic$$x0
000258916 9141_ $$y2023
000258916 9201_ $$0I:(DE-2719)1040000$$kAG Fava 2 ; AG Fava 2$$lLeitung Core Facilities$$x0
000258916 9201_ $$0I:(DE-2719)1040190$$kLAT$$lLaboratory Automation Technologies (LAT)$$x1
000258916 980__ $$apreprint
000258916 980__ $$aVDB
000258916 980__ $$aI:(DE-2719)1040000
000258916 980__ $$aI:(DE-2719)1040190
000258916 980__ $$aUNRESTRICTED